Skip to main content
NIH funding notice PAR-13-158

Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21/R33)

Closed on May 7, 2016.

Posted
March 25, 2013
Close date
May 7, 2016
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $563,807 in first-year total cost, median $281,904.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 SBIB-D (59)]1
  2. Special Emphasis Panel[ZRG1 SBIB-W (59)]1

Most frequent institutions

  1. JOHNS HOPKINS UNIVERSITY1
  2. MASSACHUSETTS GENERAL HOSPITAL1
Competing awards under PAR-13-158 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2017PET imaging of soluble epoxide hydrolase (sEH) in human subjects1R21AG054802-01HORTI, ANDREW GPOMPER, MARTIN GJOHNS HOPKINS UNIVERSITY, MD$285,822ZRG1
2016Epigenetic Mechanisms in Alcohol Use Disorder quantified by non-invasive PET imaging1R21AA025192-01WANG, CHANGNINGMASSACHUSETTS GENERAL HOSPITAL, MA$277,985ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-13-158: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21/R33) | ScienceDex | ConductScience